Upcoming events

Supported by

Stents and scaffolds

Here you will find all the latest content on stents and scaffolds published on this website. Results are listed in chronological order.Since 1986, when the first cardiovascular stent was implanted, the development of drug-eluting stents (DES) and the recent introduction of bioresorbable scaffolds have revolutionised interventional cardiology. Keep up-to-date with the latest research; evolving tools, devices and techniques; the role of adjunctive pharmacotherapy; advances in imaging techniques as well as the use of invasive imaging and functional assessment. Find out more…

Filtered By
Stents and scaffolds

550 results

Bifurcation stenting, when do I need two stents?

11 Jul 2017 - From EUROPCR 2017

Treating bifurcation lesions is a challenge, and the need to convert to a two-stent strategies can be daunting. Join experts G. G. Toth, T. Johnson and F. Mangiacapra as they discuss their own insights and suggestions, reminding us to never forget the provisional approach. What percentage of cases might necessitate converting to a two-stent technique? What elements in anatomy, lesion or the type of patient might require this change? Which two-stent strategy should you begin with – and practice? What imaging tools are useful and what possible role does functional assessment play? Watch video and find out…

Bioresorbable scaffolds, an evolving technology

10 Jul 2017 - From EUROPCR 2017

A stent that does its job and then disappear has long been an unmet need and dream of interventional cardiologists. Join J. Ormiston, A. Al Nooryani and W. Wijns as they review the state-of-the-art of these elusive devices beginning with their composition and covering the issues and implications of scaffold thickness, device cost or procedural complexity. Today, with limited trials and data, faced with the fear of a small percentage of stent thrombosis, do these devices have a true utility? What is PSP and how does that optimise the use of current BRS? What does the future hold for this new technology? Watch now…

LIVE case: new BRS for bifurcation

From EUROPCR 2017

Consult this LIVE case on new Bioresorbable scaffolds (BRS) for bifurcation lesion, which includes a LIVE demonstration from Fu Wai Hospital, National Centre for Cardiovascular Diseases - Beijing, China.

With collaboration of CIT, the PCR-CIT China Chengdu Valves Course and CBS.

Clinical case

A 58-year-old female with effort angina:

LAD/Diag 1 bifurcationBRS implantationOCT assessment

Operator

Kefei Dou

Operator

Jie Qian

Wrap-up interview - Successful left main PCI, what are the right tools and techniques?

From EUROPCR 2017

Why has this been called “the year” of Left Main interventions? A. Latib, O. Mendiz and Z. Ghazzal review the new maturity of an intervention which pioneer A. Grüntzig attempted years ago. Learn about the compelling data today from the EXCEL study showing non-inferiority of the endovascular approach and discover what is unique about the ongoing European Bifurcation Club’s EBC Main trial. Find out how these studies can impact on indications and eventual changes in future guidelines. From new devices – sizes and the choice of 1 or 2 stents – to experience and improved techniques, the critical elements of strategy and the choice of imaging for planning, optimisation and outcome: you’ll find the details here…

Resolute Onyx 2.0mm in extra small vessel primary endpoint results

14 Jun 2017 - From EUROPCR 2017

M. Price begins by reminding us that the “smaller the reference vessel diameter, the higher the rates of restenosis” even in DES, so how do you approach your patients with significant lesions in small vessels? Here we review the pitfalls of existing methods and learn about a new tool that answers to your unmet needs in this domain. A new iteration, an improved architecture for this size, and now emerging data…shouldn’t you know more about this valid option for a challenging lesion set? Watch now…

SMT and TALENT RCT in Europe

14 Jun 2017 - From EUROPCR 2017

With over 800 patients enrolled in their randomised clinical trial, SMT is convinced of the safety and efficacy of their dependable Supraflex stent. Learn the basis for their confidence with A.G. Zaman, as he introduces this new-generation DES which is safe, flexible and perhaps non-inferior to the current workhorse stent. Early positive results from a single-centre UK registry data paved the way for the implementation of the current, all-comers trial. What do we know so far and can we make any assumption from early emerging data? Join us here and find out…

Evidences on MagicTouch, the 1st sirolimus drug eluting balloon

08 Jun 2017 - From EUROPCR 2017

Can the unique formulation and design of this new drug-eluting balloon make a difference? Join A. Abizaid as he discusses the potential of an innovative device offering a more “user-friendly” and “safer” drug experience. With its encapsulated drug delivery design, see how this system can respond to your clinical needs in such situations as small vessels, in-stent restenosis or treating restenosis in a jailed side branch. Discover the results of the early and robust registry and learn about the ongoing new pan-European, “real-world” registry experience as well as the upcoming non-inferiority randomised trial. A viable tool for the future? Watch now…

Round Table - Firehawk Stent, proven fast healing from TARGET clinical program

16 Jun 2017 - From EUROPCR 2017

A new “workhorse” drug-eluting stent? Join A. Lansky and A. Baumbach as they discuss what sets the Firehawk apart from other stents available today. Learn why this ultra-thin, cobalt-chromium device, with its abluminal groove and bioresorbable polymer is unique. How this allows the stent a highly targeted delivery, allowing for a reduced drug presence. Learn about the speed of drug elution or the 5-year data from the Chinese experience. Find out about the ongoing European, all-comers non-inferiority trial further exploring the long-term efficacy and safety of this truly innovative device. What are the early results – and the promise for the future? Watch here…

Evidences from the meriT-V randomized trial on BioMime SES and from MeRes-1 Extend, MeRes100 BRS 1st in man evaluation

08 Jun 2017 - From EUROPCR 2017

Hybrid design: a new world of choice in stents and scaffolds? What is the BioMine Morp or the MeRes 100? What do they have in common with BioMime SES and how do they differ? Join A. Abizaid as he discusses these innovative solutions being developed by Meril Life. From the hybrid design itself– an architecture comprised of more closed cells at the edges of the device and more open cells in the middle – to the latest ongoing trials, first-in-man experience and studies, learn how these new devices can facilitate access, protect against injury and provide new clinical choices in the near future… Watch this three part interview now…

Wrap-up interview - Challenges in diabetic patients: EVOlving PCI's clinical outcome through innovative technology

18 May 2017 - From EUROPCR 2017

Considering the growing epidemic of diabetes mellitus, and the need for effective devices, can we improve clinical outcomes through innovative technologies? Join R. Mehran as she speaks with R. Romaguera and S. Banai and learn why physicians should consider the latest DES technology to make PCI the preferred option rather than CABAGE in diabetics patients. Then discover the Cre8 EVO, its exclusive abluminal reservoirs, unique formulation and EvenArt architecture. Find out about new clinical data, upcoming trials and why this is proving effectiveness…watch now!